MOBP

Summary

MOBP (myelin associated oligodendrocyte basic protein, HGNC:7189) is a protein-coding gene on chromosome 3p22.1, encoding Myelin-associated oligodendrocyte basic protein (Q13875). May play a role in compacting or stabilizing the myelin sheath, possibly by binding the negatively charged acidic phospholipids of the cytoplasmic membrane.

Predicted to be a structural constituent of myelin sheath. Predicted to be involved in nervous system development. Predicted to be located in mitochondrion and perinuclear region of cytoplasm. Implicated in frontotemporal dementia.

Source: NCBI Gene 4336 — RefSeq curated summary.

At a glance

• GWAS associations: 15
• Clinical variants (ClinVar): 29 total — 1 pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_001393704

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7189
Approved symbol	MOBP
Name	myelin associated oligodendrocyte basic protein
Location	3p22.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000168314
Ensembl biotype	protein_coding
OMIM	600948
Entrez	4336

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 21 protein_coding, 3 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000311042, ENST00000383754, ENST00000415443, ENST00000420739, ENST00000424090, ENST00000428261, ENST00000436143, ENST00000441980, ENST00000442631, ENST00000447324, ENST00000451925, ENST00000452959, ENST00000479860, ENST00000682069, ENST00000684792, ENST00000854240, ENST00000854241, ENST00000854242, ENST00000854243, ENST00000854244, ENST00000854245, ENST00000937495, ENST00000937496, ENST00000954235, ENST00000954236

RefSeq mRNA: 4 — MANE Select: NM_001393704 NM_001278322, NM_001278323, NM_001393704, NM_182935

CCDS: CCDS2687, CCDS2688, CCDS63598

Canonical transcript exons

ENST00000684792 — 4 exons

Exon	Start	End
ENSE00001693771	39502535	39503027
ENSE00001735986	39502066	39502275
ENSE00001738261	39480040	39480123
ENSE00001773788	39467680	39467740

Expression profiles

Bgee: expression breadth ubiquitous, 201 present calls, max score 99.92.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 26.9796 / max 3213.6831, expressed in 122 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
36142	23.6474	106
36141	2.9672	84
36143	0.1548	56
36159	0.0884	26
36145	0.0543	12
36147	0.0426	20
36146	0.0186	6
36144	0.0064	3

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
C1 segment of cervical spinal cord	UBERON:0006469	99.92	gold quality
cranial nerve II	UBERON:0000941	99.90	gold quality
pons	UBERON:0000988	99.88	gold quality
corpus callosum	UBERON:0002336	99.88	gold quality
inferior vagus X ganglion	UBERON:0005363	99.86	gold quality
spinal cord	UBERON:0002240	99.85	gold quality
subthalamic nucleus	UBERON:0001906	99.84	gold quality
superior vestibular nucleus	UBERON:0007227	99.83	gold quality
substantia nigra pars reticulata	UBERON:0001966	99.64	gold quality
medial globus pallidus	UBERON:0002477	99.62	gold quality
globus pallidus	UBERON:0001875	99.57	gold quality
medulla oblongata	UBERON:0001896	99.57	gold quality
substantia nigra pars compacta	UBERON:0001965	99.42	gold quality
ventral tegmental area	UBERON:0002691	99.35	gold quality
dorsal plus ventral thalamus	UBERON:0001897	99.32	gold quality
midbrain	UBERON:0001891	99.19	gold quality
endothelial cell	CL:0000115	99.18	gold quality
amygdala	UBERON:0001876	99.17	gold quality
substantia nigra	UBERON:0002038	99.16	gold quality
inferior olivary complex	UBERON:0002127	99.16	gold quality
lateral globus pallidus	UBERON:0002476	99.12	gold quality
hypothalamus	UBERON:0001898	98.76	gold quality
lateral nuclear group of thalamus	UBERON:0002736	98.66	gold quality
Ammon’s horn	UBERON:0001954	98.39	gold quality
putamen	UBERON:0001874	98.38	gold quality
Brodmann (1909) area 46	UBERON:0006483	97.91	gold quality
caudate nucleus	UBERON:0001873	97.53	gold quality
nucleus accumbens	UBERON:0001882	97.51	gold quality
parietal lobe	UBERON:0001872	97.28	gold quality
temporal lobe	UBERON:0001871	97.10	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-GEOD-180759	yes	2946.35
E-HCAD-35	yes	2025.94
E-HCAD-25	yes	1911.48
E-GEOD-84465	yes	12.84
E-ANND-3	yes	6.29
E-MTAB-7303	no	2.34

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

118 targeting MOBP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4779	99.86	66.50	1583
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-200A-5P	99.76	69.10	949
HSA-MIR-200B-5P	99.76	69.05	948
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-12130	99.75	65.47	452
HSA-MIR-378G	99.71	64.90	1106
HSA-MIR-4716-3P	99.69	66.73	1022
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-6513-3P	99.59	69.77	1102

Literature-anchored findings (GeneRIF, showing 12)

• Decreased expression of a number of myelin-related genes, including myelin basic protein (MBP), proteolipid protein (PLP), and myelin-associated oligodendrocyte basic protein (MOBP) was noted in nucleus accumbens of cocaine abusers (PMID:15009677)
• MOBP mRNA levels were increased in the DLPFC white matter in patients with a history of substance abuse. (PMID:17964117)
• Genotypes at MOBP and EIF2AK3 confer risk predominantly in APOE epsilon4-positive subjects, with indications of an interaction between APOE and MOBP or EIF2AK3 on Alzheimer’s disease risk. (PMID:23116876)
• The rs1768208 risk polymorphism in MOBP has prognostic value in behavioral-variant frontotemporal dementia. (PMID:24994843)
• rs1768208 is associated with corticobasal degeneration. (PMID:26077951)
• Mutation in MOBP gene is associated with amyotrophic lateral sclerosis. (PMID:27455348)
• Dentate gyrus volume deficit in schizophrenia. (PMID:31155012)
• Study shoes that myelin-associated oligodendrocytic basic protein immunoreactivity is present in the core of Lewy bodies in Parkinson’s disease and dementia with Lewy Bodies. (PMID:31183926)
• White matter DNA methylation profiling reveals deregulation of HIP1, LMAN2, MOBP, and other loci in multiple system atrophy. (PMID:31535203)
• MOBP and HIP1 in multiple system atrophy: New alpha-synuclein partners in glial cytoplasmic inclusions implicated in the disease pathogenesis. (PMID:33368549)
• Myelin-associated oligodendrocyte basic protein rs616147 polymorphism as a risk factor for Parkinson’s disease. (PMID:34694630)
• MOBP rs616147 Polymorphism and Risk of Amyotrophic Lateral Sclerosis in a Greek Population: A Case-Control Study. (PMID:34946282)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	myripb	ENSDARG00000038814
danio_rerio	myripa	ENSDARG00000075706
mus_musculus	Mobp	ENSMUSG00000032517
rattus_norvegicus	Mobp	ENSRNOG00000018700

Paralogs (2): MLPH (ENSG00000115648), MYRIP (ENSG00000170011)

Protein

Protein identifiers

Myelin-associated oligodendrocyte basic protein — Q13875 (reviewed: Q13875)

All UniProt accessions (5): A0A024R2P3, A0A0S2Z3W1, C9JAR7, C9JLT8, Q13875

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in compacting or stabilizing the myelin sheath, possibly by binding the negatively charged acidic phospholipids of the cytoplasmic membrane.

Subcellular location. Cytoplasm. Perinuclear region.

Isoforms (4)

UniProt ID	Names	Canonical?
Q13875-1	1, OPRP2	yes
Q13875-2	2, OPRP1
Q13875-3	3
Q13875-4	4

RefSeq proteins (4): NP_001265251, NP_001265252, NP_001380633, NP_891980 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR041282	FYVE_2	Domain
IPR051745	Intracell_Transport_Effector	Family

Pfam: PF02318

UniProt features (20 total): repeat 4, compositionally biased region 4, splice variant 4, sequence conflict 3, modified residue 2, region of interest 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q13875-F1	55.69	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 99, 109

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-8986944	Transcriptional Regulation by MECP2
R-HSA-212436	Generic Transcription Pathway
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)

MSigDB gene sets: 103 (showing top): ASTON_MAJOR_DEPRESSIVE_DISORDER_DN, MODULE_205, MODULE_206, HNF4_DR1_Q3, chr3p22, HOSHIDA_LIVER_CANCER_LATE_RECURRENCE_DN, KANG_IMMORTALIZED_BY_TERT_DN, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_UP, TGGAAA_NFAT_Q4_01, LEIN_OLIGODENDROCYTE_MARKERS, GOCC_RIBONUCLEOPROTEIN_GRANULE, LINDGREN_BLADDER_CANCER_CLUSTER_1_DN, HSF2_01, GOMF_STRUCTURAL_MOLECULE_ACTIVITY

GO Biological Process (1): nervous system development (GO:0007399)

GO Molecular Function (2): structural constituent of myelin sheath (GO:0019911), protein binding (GO:0005515)

GO Cellular Component (3): mitochondrion (GO:0005739), perinuclear region of cytoplasm (GO:0048471), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Generic Transcription Pathway	1
RNA Polymerase II Transcription	1
Gene expression (Transcription)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
cellular anatomical structure	2
system development	1
structural molecule activity	1
myelin sheath	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1126 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MOBP	PLP1	P04400	790
MOBP	CNP	P09543	725
MOBP	MBP	P02686	635
MOBP	OPALIN	Q96PE5	634
MOBP	MOG	Q16653	632
MOBP	CLDN11	O75508	589
MOBP	STX6	O43752	583
MOBP	OLIG1	Q8TAK6	582
MOBP	ERMN	Q8TAM6	579
MOBP	PLLP	Q9Y342	575
MOBP	MAG	P20916	567
MOBP	MYRF	Q9Y2G1	565
MOBP	OLIG2	Q13516	553
MOBP	UNC13A	Q9UPW8	513
MOBP	DRD2	P14416	503

IntAct

38 interactions, top by confidence:

A	B	Type	Score
MOBP	KRTAP10-9	psi-mi:“MI:0915”(physical association)	0.720
KRTAP10-9	MOBP	psi-mi:“MI:0915”(physical association)	0.720
MOBP		psi-mi:“MI:0915”(physical association)	0.560
	MOBP	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-5	MOBP	psi-mi:“MI:0915”(physical association)	0.560
MOBP	KRTAP10-7	psi-mi:“MI:0915”(physical association)	0.560
MOBP	KRTAP10-5	psi-mi:“MI:0915”(physical association)	0.560
MOBP	KRT40	psi-mi:“MI:0915”(physical association)	0.560
MOBP	KRTAP10-8	psi-mi:“MI:0915”(physical association)	0.560
MOBP	MEOX2	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (27): KRTAP10-7 (Two-hybrid), KRTAP10-9 (Two-hybrid), KRTAP10-1 (Two-hybrid), KRTAP10-5 (Two-hybrid), KRTAP10-3 (Two-hybrid), KRTAP10-9 (Two-hybrid), KRTAP10-1 (Two-hybrid), KRTAP10-8 (Two-hybrid), KRTAP10-3 (Two-hybrid), MEOX2 (Two-hybrid), WAC (Two-hybrid), KRT40 (Two-hybrid), MOBP (Two-hybrid), MOBP (Two-hybrid), MOBP (Two-hybrid)

ESM2 similar proteins: A3EXH0, A3GGT2, A4H824, A7XCE1, A7XCE8, K9N4Q4, O60356, O97965, P03267, P04614, P06921, P0C674, P0C724, P13275, P16909, P24938, P30117, P30415, P36717, P56620, P61927, P61928, P68950, P68951, P79244, P83474, Q09505, Q09507, Q09821, Q13875, Q28337, Q3KSS1, Q3UC65, Q5U2S0, Q5UPY2, Q63327, Q6C0K1, Q6GZN6, Q6UDL8, Q89532

Diamond homologs: A8T6P4, M3WHG5, Q13875, Q63327, Q7TNY7, Q8K3I4, Q8NFW9, Q8VHQ7, Q91V27, Q96C24, Q9BV36, Q9D2P8, Q9R0Q1, Q4VX76, Q80T23, Q812E4, Q8TDW5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

29 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	12
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1455527	NC_000003.11:g.(?16710965)(41275270_?)del	Pathogenic

SpliceAI

783 predictions. Top by Δscore:

Variant	Effect	Δscore
3:39502040:T:TA	acceptor_gain	1.0000
3:39502048:T:A	acceptor_loss	1.0000
3:39502048:T:TA	acceptor_gain	1.0000
3:39502051:A:AG	acceptor_gain	1.0000
3:39502051:ATC:A	acceptor_gain	1.0000
3:39502051:ATCG:A	acceptor_gain	1.0000
3:39502052:T:G	acceptor_gain	1.0000
3:39502053:C:A	acceptor_gain	1.0000
3:39502054:G:A	acceptor_gain	1.0000
3:39502056:C:CA	acceptor_gain	1.0000
3:39502063:CAG:C	acceptor_loss	1.0000
3:39502064:AG:A	acceptor_loss	1.0000
3:39502064:AGT:A	acceptor_gain	1.0000
3:39502065:G:GT	acceptor_gain	1.0000
3:39502065:G:T	acceptor_loss	1.0000
3:39502065:GT:G	acceptor_gain	1.0000
3:39502065:GTG:G	acceptor_gain	1.0000
3:39502065:GTGA:G	acceptor_gain	1.0000
3:39502272:CCAGG:C	donor_loss	1.0000
3:39502273:CAGGT:C	donor_loss	1.0000
3:39502274:AGG:A	donor_loss	1.0000
3:39502275:GGTA:G	donor_loss	1.0000
3:39502276:GTAA:G	donor_loss	1.0000
3:39502277:T:G	donor_loss	1.0000
3:39513376:A:AG	acceptor_gain	1.0000
3:39513379:CCA:C	acceptor_loss	1.0000
3:39513380:CA:C	acceptor_loss	1.0000
3:39513381:A:AC	acceptor_loss	1.0000
3:39513382:G:A	acceptor_loss	1.0000
3:39502064:A:AG	acceptor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000008865 (3:39522550 C>T), RS1000039002 (3:39528224 C>T), RS1000055228 (3:39526534 C>T), RS1000173231 (3:39475504 A>G), RS1000182677 (3:39516095 A>G), RS1000206128 (3:39466834 T>C), RS1000230796 (3:39468766 G>A), RS1000236975 (3:39529578 C>T), RS1000256462 (3:39496187 T>C), RS1000258434 (3:39467156 G>A,C), RS1000271066 (3:39527457 G>T), RS1000372507 (3:39472267 C>G,T), RS1000447442 (3:39509788 T>C), RS1000485520 (3:39529847 C>T), RS1000485799 (3:39473634 T>G)

Disease associations

OMIM: gene MIM:600948 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): amyotrophic lateral sclerosis (MONDO:0004976)

Orphanet (1): Amyotrophic lateral sclerosis (Orphanet:803)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0007354	Amyotrophic lateral sclerosis

GWAS associations

15 associations (top):

Study	Trait	p-value
GCST000246_3	Attention deficit hyperactivity disorder	1.000000e-08
GCST000477_32	Cognitive performance	4.000000e-06
GCST001116_3	Progressive supranuclear palsy	5.000000e-17
GCST001915_5	Alzheimer’s disease (cognitive decline)	1.000000e-07
GCST002971_1	Corticobasal degeneration	2.000000e-07
GCST004692_2	Amyotrophic lateral sclerosis	4.000000e-10
GCST004901_4	Amyotrophic lateral sclerosis (sporadic)	2.000000e-08
GCST006418_6	Progressive supranuclear palsy	7.000000e-19
GCST008557_1	Dentate gyrus volume x schizophrenia interaction	5.000000e-08
GCST010698_19	Subcortical volume (min-P)	1.000000e-08
GCST010699_88	Brain morphology (min-P)	1.000000e-13
GCST010701_114	Cortical surface area (MOSTest)	1.000000e-11
GCST010702_154	Subcortical volume (MOSTest)	5.000000e-30
GCST010703_213	Brain morphology (MOSTest)	3.000000e-11
GCST90000025_734	Appendicular lean mass	2.000000e-11

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0003926	neuropsychological test
EFO:0004346	neuroimaging measurement
EFO:0004980	appendicular lean mass

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D000690	Amyotrophic Lateral Sclerosis	C10.228.854.139; C10.574.562.250; C10.574.950.050; C10.668.467.250; C18.452.845.800.050

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs616147	Efficacy	3	creatine	Amyotrophic Lateral Sclerosis

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs616147	MOBP	3	2.00	1	creatine

CTD chemical–gene interactions

9 total (human), top 9 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects methylation, increases expression	2
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression	2
bisphenol A	increases methylation	1
CGP 52608	affects binding, increases reaction	1
Mercuric Chloride	increases expression	1
Methotrexate	decreases expression	1
Silicon Dioxide	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	decreases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00542412	PHASE4	COMPLETED	CARE Canadian ALS Riluzole Evaluation
NCT00560287	PHASE4	UNKNOWN	Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis
NCT00613899	PHASE4	COMPLETED	Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS)
NCT04997954	PHASE4	UNKNOWN	EMERALD TRIAL Open Label Extension Study
NCT06849115	PHASE4	COMPLETED	Effects of L-Carnitine in Amyotrophic Lateral Sclerosis Patients With CHCHD10 Mutations
NCT07223723	PHASE4	RECRUITING	A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Chinese Participants With SOD-1 Amyotrophic Lateral Sclerosis (ALS)
NCT00021697	PHASE3	COMPLETED	Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
NCT00035815	PHASE3	COMPLETED	Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial
NCT00047723	PHASE3	COMPLETED	Minocycline to Treat Amyotrophic Lateral Sclerosis
NCT00069186	PHASE3	UNKNOWN	Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis
NCT00136110	PHASE3	COMPLETED	Trial of Sodium Valproate in Amyotrophic Lateral Sclerosis
NCT00330681	PHASE3	COMPLETED	Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
NCT00349622	PHASE3	COMPLETED	Clinical Trial Ceftriaxone in Subjects With ALS
NCT00372879	PHASE3	COMPLETED	Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS
NCT00415519	PHASE3	COMPLETED	Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III
NCT00424463	PHASE3	COMPLETED	Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT00839033	PHASE3	TERMINATED	Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders
NCT00868166	PHASE3	COMPLETED	Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
NCT00965497	PHASE3	COMPLETED	Escitalopram (Lexapro) for Depression MS or ALS
NCT01016522	PHASE3	TERMINATED	Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)
NCT01160263	PHASE3	COMPLETED	Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls
NCT01281189	PHASE3	COMPLETED	Phase 3 Study of Dexpramipexole in ALS
NCT01492686	PHASE3	COMPLETED	Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
NCT01583088	PHASE3	TERMINATED	Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation
NCT01622088	PHASE3	TERMINATED	Phase 3 Extension Study of Dexpramipexole in ALS
NCT02496767	PHASE3	COMPLETED	Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
NCT02623699	PHASE3	COMPLETED	An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
NCT02936635	PHASE3	COMPLETED	A Study for Patients Who Completed VITALITY-ALS (CY 4031)
NCT03127267	PHASE3	RECRUITING	Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
NCT03280056	PHASE3	COMPLETED	Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients
NCT03491462	PHASE3	COMPLETED	Arimoclomol in Amyotropic Lateral Sclerosis
NCT03505021	PHASE3	COMPLETED	Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
NCT03548311	PHASE3	COMPLETED	Clinical Trial of Ultra-high Dose Methylcobalamin for ALS
NCT03690791	PHASE3	UNKNOWN	Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease
NCT03800524	PHASE3	UNKNOWN	Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS
NCT03836716	PHASE3	TERMINATED	Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial
NCT03948178	PHASE3	TERMINATED	Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
NCT04165824	PHASE3	COMPLETED	Safety Study of Oral Edaravone Administered in Subjects With ALS
NCT04248465	PHASE3	TERMINATED	An Efficacy and Safety Study of Ravulizumab in ALS Participants
NCT04569084	PHASE3	TERMINATED	Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS